Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
The once-in-a-lifetime treatment with Abciximab Intracoronary for acute coronary syndrome and a second dose intravenously for atrial fibrillation is recommended for adults with high blood pressure.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
- L. Wallentin, R. Becker, M. Thorsén
- Medicine, BiologyThe New England journal of medicine
- 10 September 2009
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of…
Authors/Task Force Members: Ph.D.s, undergraduates, post-graduate students, academics, and others.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding.
Platelet inhibition with cangrelor in patients undergoing PCI.
Cangrelor was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours.
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on…
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate- to-severe secondary hyperparathyroidism who were undergoing dialysis.